Immune Receptor LAIR1 Slows Leukemia Cell Growth by Triggering Cell Cycle Arrest and Apoptosis

Chronic lymphocytic leukemia (CLL) remains one of the most common hematological malignancies in adults, characterized by the gradual accumulation of mature but dysfunctional B lymphocytes in the blood, bone marrow, and lymphoid tissues. While targeted therapies directed against Bruton’s tyrosine kinase (BTK) and the anti-apoptotic protein BCL-2 have transformed the treatment landscape in recent years, the disease remains incurable for most patients, and the molecular events that govern its slow but relentless progression are still incompletely understood. A new study published in Annals of Hematology now adds an intriguing piece to this puzzle, pointing to an unexpected player: LAIR1, the leukocyte-associated immunoglobulin-like receptor 1, a molecule better known for its role in dampening immune cell activation.

The research, led by Min Min, Jun Zhang, Jingjing Wang, Yin Chen, and Hewei Luan of the Department of Laboratory Medicine at Jurong Hospital, Jiangsu University, in Zhenjiang, China, set out to clarify what LAIR1 actually does in CLL. LAIR1 is an inhibitory receptor expressed on the surface of many immune cells, including natural killer cells, T cells, B cells, and myeloid lineages. Its cytoplasmic tail carries immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, upon ligand binding, recruit phosphatases that blunt cellular activation signals. In the context of cancer, inhibitory receptors have typically been viewed through the lens of immune evasion, as tumors can exploit such pathways to escape immune surveillance. The new findings, however, suggest that in CLL the story may be more nuanced, with LAIR1 expression levels correlating with disease outcome in a way that hints at a protective role.

To dissect the cellular landscape of CLL, the team began with single-cell RNA sequencing analysis, a technique that allows researchers to profile gene expression in individual cells rather than in bulk tissue samples. Using uniform manifold approximation and projection (UMAP) for dimensionality reduction and principal component analysis to characterize transcriptional variation, they mapped the cellular signatures within CLL samples and identified the key cell populations populating the leukemic microenvironment. Among these, macrophages emerged as a particularly important population, exhibiting the highest expression of LAIR1 of any cell type examined. This observation is notable because tumor-associated macrophages are increasingly recognized as central architects of the tumor microenvironment in many malignancies, shaping immune responses, supporting tissue remodeling, and influencing treatment response.

With the cellular context established, the investigators turned to comparative expression analysis. Drawing on public datasets, including resources from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), they compared LAIR1 expression between CLL samples and healthy control samples. The results were consistent across bioinformatic and experimental approaches: LAIR1 expression was significantly decreased in CLL compared with controls. This downregulation raised an immediate clinical question. If LAIR1 is lost as the disease develops, does the degree of loss carry prognostic weight? To answer this, the team stratified CLL patients into two groups according to the optimal cutoff value of LAIR1 expression and compared their survival outcomes using Kaplan-Meier analysis.

The survival analysis delivered a striking result. Patients in the low LAIR1 expression group had significantly worse prognosis than those whose tumors retained higher levels of the receptor. In other words, the more LAIR1 expression was diminished, the poorer the clinical outlook. This kind of expression-outcome relationship does not by itself prove causation, but it provides a compelling correlation that justified the next phase of the study: directly testing what LAIR1 does to leukemic cells when its expression is experimentally restored. Correlative findings in cancer genomics frequently dissolve under functional scrutiny, so the team designed a series of laboratory experiments to move from association toward mechanism.

The functional work centered on a human CLL cell line. The researchers constructed LAIR1 overexpression variants of these cells and confirmed that the receptor was genuinely upregulated at both the messenger RNA and protein levels, using real-time quantitative polymerase chain reaction (RT-qPCR) and Western blotting respectively. RT-qPCR amplifies complementary DNA copies of specific transcripts to quantify gene expression with high sensitivity, while Western blotting uses antibody-based detection to measure protein abundance, and agreement between the two methods gave the team confidence that their engineered cell lines faithfully reflected LAIR1 overexpression. With the model system validated, they proceeded to the central question: what happens to CLL cells when LAIR1 is abundantly present?

The answer came from flow cytometry, a technique that passes thousands of individual cells in rapid succession through laser beams, allowing researchers to quantify fluorescent signals attached to specific cellular features. By staining cells with propidium iodide (PI), a dye whose uptake reflects DNA content, the team could determine the distribution of cells across the phases of the cell cycle. By applying annexin-based apoptosis assays, they could measure the fraction of cells undergoing programmed cell death. The results were clear and internally consistent. CLL cells engineered to overexpress LAIR1 displayed a shortened S phase, the portion of the cell cycle devoted to DNA replication, and exhibited significantly increased rates of apoptosis. In effect, restoring LAIR1 pushed the leukemic cells away from proliferation and toward self-destruction.

These findings carry conceptual weight because they link an immune inhibitory receptor to the core proliferative machinery of the cancer cell itself. A shortened S phase combined with elevated apoptosis suggests that LAIR1 overexpression disrupts the carefully balanced cell cycle regulation that allows CLL cells to accumulate slowly over years. CLL is notorious for its dependence on anti-apoptotic signaling, particularly through the BCL-2 family of proteins, which is precisely why BCL-2 inhibitors such as venetoclax have proven so effective in the clinic. The observation that LAIR1 overexpression increases apoptotic rates places the receptor on the same functional axis as the pathways that current drugs target, albeit from a different molecular entry point. Whether LAIR1 acts directly on cell cycle regulators or indirectly through downstream signaling from its ITIM motifs remains an open question that the study does not fully resolve, but the phenotypic effect is unambiguous in the experimental system used.

The macrophage connection adds a further layer of biological interest. The single-cell analysis identified macrophages as the highest LAIR1-expressing cells in the CLL microenvironment, which raises the possibility that the receptor’s influence on disease progression is mediated, at least in part, through the tumor microenvironment rather than through the malignant B cells alone. Tumor-associated macrophages can adopt polarized states that either support or suppress tumor growth, and inhibitory receptors like LAIR1 are key regulators of macrophage activation. A scenario in which reduced LAIR1 expression licenses macrophages toward a more tumor-permissive state, while simultaneously removing a brake on leukemic cell cycling, would fit the clinical observation that low LAIR1 predicts worse survival. Disentangling these cell-intrinsic and microenvironmental contributions will be an important task for future studies.

The authors are careful to frame their conclusions appropriately, describing the work as offering a novel reference for the effect of LAIR1 in CLL rather than as an immediate therapeutic blueprint. The study was supported by the Jurong City Social Development Science and Technology Planning Project under grant number ZA42203, and the authors declared no competing interests. Published open access on 1 September 2026 in Annals of Hematology, the paper arrives at a moment when the field is actively searching for biomarkers that can refine risk stratification beyond the existing clinical and genetic markers, such as immunoglobulin heavy chain variable region mutation status and cytogenetic abnormalities. If LAIR1 expression can be validated as a prognostic marker in larger, independent cohorts, it could eventually help clinicians identify which patients need earlier intervention. And if the functional findings hold up, pharmacological strategies aimed at restoring or mimicking LAIR1 signaling might one day complement BTK and BCL-2 inhibition, attacking the disease from yet another angle. For now, the study stands as a reminder that some of the most informative clues about cancer biology come from molecules that were hiding in plain sight on the surface of the immune system’s own cells.

Subject of Research: The role of the LAIR1 immune receptor in regulating cell cycle progression and apoptosis in chronic lymphocytic leukemia

Article Title: LAIR1 regulated the development of chronic lymphocytic leukemia by modulating cell cycle and apoptosis

Article References: Min, M., Zhang, J., Wang, J., Chen, Y., & Luan, H. (2026). LAIR1 regulated the development of chronic lymphocytic leukemia by modulating cell cycle and apoptosis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07263-y

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07263-y

Keywords: chronic lymphocytic leukemia, LAIR1, cell cycle, apoptosis, single-cell RNA sequencing, macrophages, tumor microenvironment, flow cytometry, Kaplan-Meier survival analysis, RT-qPCR, Western blot, hematology